EP
UTHR icon

Eversept Partners’s United Therapeutics UTHR Stock Holding History

Eversept Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156M Buy
287,668
+23,397
+9% +$13.2M 8.09% 1
2026
Q1 		$157M Buy
264,271
+11,679
+5% +$5.82M 8.26% 1
2025
Q4 		$123M Sell
252,592
-628
-0.2% -$292K 6.2% 4
2025
Q3 		$106M Buy
253,220
+193,854
+327% +$65.2M 7.32% 2
2025
Q2 		$17.1M Buy
59,366
+1,877
+3% +$561K 1.57% 23
2025
Q1 		$17.7M Buy
57,489
+13,786
+32% +$4.72M 1.8% 20
2024
Q4 		$15.4M Sell
43,703
-87,246
-67% -$32.1M 1.37% 17
2024
Q3 		$46.9M Sell
130,949
-104,402
-44% -$35.3M 3.21% 13
2024
Q2 		$75M Sell
235,351
-15,784
-6% -$4.18M 5.13% 6
2024
Q1 		$57.7M Buy
251,135
+4,901
+2% +$1.11M 3.85% 8
2023
Q4 		$54.1M Sell
246,234
-21,669
-8% -$4.99M 4.76% 8
2023
Q3 		$60.5M Buy
267,903
+7,505
+3% +$1.73M 5.12% 6
2023
Q2 		$57.5M Buy
260,398
+38,291
+17% +$8.48M 4.81% 6
2023
Q1 		$49.7M Sell
222,107
-10,680
-5% -$2.63M 3.47% 7
2022
Q4 		$64.7M Sell
232,787
-22,439
-9% -$5.66M 5.67% 6
2022
Q3 		$53.4M Sell
255,226
-55,608
-18% -$12.4M 4.63% 7
2022
Q2 		$73.2M Buy
310,834
+18,600
+6% +$3.78M 5.21% 4
2022
Q1 		$52.4M Sell
292,234
-99,686
-25% -$19M 4.03% 7
2021
Q4 		$84.7M Sell
391,920
-52,551
-12% -$10.3M 5.41% 4
2021
Q3 		$82M Buy
444,471
+1,526
+0.3% +$301K 5.67% 1
2021
Q2 		$79.5M Sell
442,945
-43,584
-9% -$8.3M 5.3% 3
2021
Q1 		$81.4M Buy
486,529
+27,893
+6% +$4.65M 4.22% 4
2020
Q4 		$69.6M Buy
458,636
+217,732
+90% +$28.6M 8.17% 2
2020
Q3 		$24.3M Buy
240,904
+8,228
+4% +$903K 5.41% 5
2020
Q2 		$28.2M Buy
+232,676
New +$26.2M 3.86% 8

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Eversept Partners's UTHR Position: Q2 2026 in Review

Eversept Partners increased its United Therapeutics (UTHR) stake by 8.9% in Q2 2026, buying an estimated $13.2M and bringing the position to 287,668 shares worth $156M. The position accounts for 8.09% of the portfolio, ranked #1.

Eversept Partners first reported a position in UTHR in Q2 2020 and has held it in 25 quarters since. The position peaked at $157M in Q1 2026. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Eversept Partners held 287,668 shares of United Therapeutics worth $156M as of Q2 2026.
  • Eversept Partners bought 23,397 United Therapeutics shares in Q2 2026, an estimated $13.2M.
  • United Therapeutics made up 8.09% of Eversept Partners's portfolio in Q2 2026, its #1 holding.
  • Eversept Partners first reported a position in United Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Eversept Partners's United Therapeutics position peaked at $157M in Q1 2026.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.